Tech Company Inital Public Offerings
Oncobiologics IPO
Oncobiologics was purchased by . Shares became public on 5/13/2016.
Transaction Overview
Company Name
Announced On
5/13/2016
Transaction Type
IPO
Amount
$34,800,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering as follows: approximately $20.0 million to advance clinical development of ONS-3010 through Phase 3 clinical trials; approximately $5.0 million to fund our other ongoing research and development activities, including advancing development of ONS-1045 to be ready to enter a Phase 3 clinical trial, and advancing development of ONS-1050 and ONS-4010 to be ready to enter Phase 1 clinical trials; and the remainder for working capital and general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7 Clarke Dr.
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Oncobiologics is committed to advancing biotherapeutics to treat serious diseases, including cancer and immune disorders through the development of both novel molecules using the TRIDENT� platform and biosimilar monocolonal antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lawrence Kenyon
Chief Medical Officer
Kenneth Bahrt
VP - Bus. Development
Stephen McAndrew
VP - Manufacturing
Chuck Hart
VP - Regulatory Affairs
Myrna Thomas
Browse more venture capital transactions:
Prev: 5/13/2016: Monica + Andy venture capital transaction
Next: 5/13/2016: Wickr venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs